Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized sto ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Replimune securities during the Class Period you may be entitled to comp ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors who purchased Replimune securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial's prospects, which the FDA deemed inadequate [5]. - It is claimed that the defendants knew or should have known about material issues affecting the trial, leading to misleading statements about Replimune's business and operations [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

NEW YORK--(BUSINESS WIRE)---- $REPL #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune†or the "Company†) (NASDAQ: REPL). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On July 22, 2025, before the market opened, Re ...

SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall. A newly filed securities class action accuses the biotech firm and its leadership of concealing critical risks tied to its flagship cancer therapy, RP1, and overstating the strength of clinical trial data used to support its FDA application. The lawsuit, filed on behalf of investors who acquired Replimune stock between N ...

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for allegedly making false and misleading statements regarding the IGNYTE trial, which led to investor losses during the specified class period [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Replimune securities between November 22, 2024, and July 21, 2025, with a deadline of September 22, 2025, for investors to apply as lead plaintiffs [1]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, resulting in the FDA deeming the trial inadequate [3]. Investor Information - Investors who suffered losses or have questions regarding their rights are encouraged to contact the law firm for more information [4]. - The law firm emphasizes that there is no cost or obligation for investors to inquire about their claims [4]. Law Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [1][3]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Replimune between November 22, 2024, and July 21, 2025, to contact them regarding their legal rights [1]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [3]. - The lawsuit claims that the misleading statements about Replimune's business and operations led to investor damages when the true details were revealed [3]. Group 3: Market Reaction - Following the announcement of a Complete Response Letter from the FDA regarding the Biologics License Application for RP1, Replimune's stock fell over 73% during intraday trading on July 22, 2025 [4].

Core Points - Rosen Law Firm is reminding purchasers of Replimune Group, Inc. securities about a class action lawsuit with a lead plaintiff deadline of September 22, 2025 [1][3] - Investors who purchased Replimune securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Case Details - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [5] - As a result of these misleading statements, investors suffered damages when the true details were revealed [5] Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6] - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7] Rosen Law Firm's Credentials - The firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4]

Core Viewpoint - Replimune Group, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the prospects of its IGNYTE trial, which led to a significant stock price drop after the FDA's response [4][5]. Group 1: Company Overview - Replimune is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for cancer treatment [3]. Group 2: Legal Allegations - The class action lawsuit claims that Replimune's management made false and misleading statements about the IGNYTE trial, which they knew or should have known were overstated [4]. - The lawsuit highlights that the FDA deemed the IGNYTE trial inadequate and not well-controlled, impacting the company's credibility [4]. Group 3: Financial Impact - Following the FDA's issuance of a Complete Response Letter regarding the Biologics License Application for RP1, Replimune's stock price plummeted by over 77% [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial's prospects, which were known to be inadequate by the defendants [5]. - The U.S. Food and Drug Administration (FDA) deemed the IGNYTE trial inadequate and not well-controlled, impacting the credibility of Replimune's business statements [5]. - Investors suffered damages when the true details about the trial and the company's operations were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in recovering funds for clients [4].